A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer
Latest Information Update: 21 Oct 2020
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Cancer pain
- Focus Adverse reactions
- Sponsors Sorrento Therapeutics
- 30 Sep 2020 Status changed from active, no longer recruiting to completed, according to a Sorrento Therapeutics, ViralClear Pharmaceuticals media release.
- 22 Sep 2020 According to Sorrento Therapeutics media release, enrollment of dose escalation cohorts has completed.
- 22 Sep 2020 Results presented in the Sorrento Therapeutics media release.